不同剂量钆喷酸葡胺增强后新发多发性硬化病灶的MRI演变

MRI evolution of new MS lesions enhancing after different doses of gadolinium.

作者信息

Rovaris M, Mastronardo G, Gasperini C, Prandini F, Yousry T A, Filippi M

机构信息

Neuroimaging Research Unit, IRCCS Ospedale San Raffaele, University of Milan, Italy.

出版信息

Acta Neurol Scand. 1998 Aug;98(2):90-3. doi: 10.1111/j.1600-0404.1998.tb01725.x.

DOI:10.1111/j.1600-0404.1998.tb01725.x

PMID:9724005

Abstract

OBJECTIVE

To investigate the evolution of multiple sclerosis (MS) lesions enhancing after single dose (SD) or triple dose (TD) of gadolinium-DTPA (Gd).

MATERIAL AND METHODS

For 3 months, 30 relapsing-remitting MS patients underwent 2 monthly MRI sessions, consisting of Gd-enhanced T1-weighted scans, after SD (i.e., 0.1 mmol/kg) in one session and TD (i.e., 0.3 mmol/kg) in the other. New enhancing lesions on month 1 and month 2 follow-up scans were studied and for them any persistence of enhancement was evaluated on the scans obtained the next month.

RESULTS

In all, 151 lesions enhancing after both SD and TD and 91 lesions enhancing only after TD entered the analysis. After 1 month, for the 151 lesions enhancing after both SD and TD, 73 (48%) were not enhancing, 50 (33%) were still enhancing after both SD and TD and 28 (19%) were enhancing only after TD. For the 91 lesions enhancing only after TD, 61 (67%; P<0.005) were not enhancing, 16 (18%; P<0.01) were still enhancing only after TD and 14 (15%; P=NS) showed enhancement after both SD and TD.

CONCLUSION

Enhancing lesions in patients with MS are heterogeneous. Those enhancing only after TD of Gd are characterized by a milder and shorter opening of the blood-brain barrier.

摘要

目的

研究单剂量（SD）或三剂量（TD）钆喷酸葡胺（Gd）增强后多发性硬化（MS）病灶的演变情况。

材料与方法

30例复发缓解型MS患者在3个月内每月接受2次MRI检查，其中一次检查采用SD（即0.1 mmol/kg）钆喷酸葡胺增强T1加权扫描，另一次采用TD（即0.3 mmol/kg）。研究第1个月和第2个月随访扫描时新出现的强化病灶，并在下个月获得的扫描图像上评估这些病灶强化的持续情况。

结果

共有151个在SD和TD增强后均出现强化的病灶以及91个仅在TD增强后出现强化的病灶纳入分析。1个月后，对于151个在SD和TD增强后均出现强化的病灶，73个（48%）不再强化，50个（33%）在SD和TD增强后仍有强化，28个（19%）仅在TD增强后有强化。对于91个仅在TD增强后出现强化的病灶，61个（67%；P<0.005）不再强化，16个（18%；P<0.01）仅在TD增强后仍有强化，14个（15%；P=无显著差异）在SD和TD增强后均出现强化。